EVGN
Evogene
NASDAQ: EVGN · HEALTHCARE · BIOTECHNOLOGY
$0.78
+2.88% today
Updated 2026-04-30
Market cap
$9.54M
P/E ratio
—
P/S ratio
2.48x
EPS (TTM)
$-1.70
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Evogene (EVGN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-220.20%
Operating margin
-1,582.00%
ROE
-100.70%
ROA
-28.80%
Debt/equity
2.21x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $14.90M | $645000.00 | 38.68% | -21.33% | 4.33% |
| 2012 | $17.07M | $-2.52M | 38.64% | -18.50% | -14.77% |
| 2013 | $17.58M | $-8.88M | 36.61% | -49.60% | -50.50% |
| 2014 | $14.51M | $-14.53M | 24.48% | -105.13% | -100.13% |
| 2015 | $11.13M | $-17.21M | 12.57% | -161.03% | -154.67% |
| 2016 | $6.54M | $-19.59M | -11.90% | -322.46% | -299.57% |
| 2017 | $3.38M | $-20.84M | -38.45% | -644.34% | -616.33% |
| 2018 | $1.75M | $-20.76M | -89.52% | -1,216.60% | -1,188.21% |
| 2019 | $753000.00 | $-18.11M | -312.08% | -3,019.92% | -2,405.31% |
| 2020 | $1.04M | $-23.37M | -217.40% | -2,580.29% | -2,247.50% |
| 2021 | $930000.00 | $-27.79M | -222.69% | -3,386.02% | -2,988.49% |
| 2022 | $1.68M | $-26.64M | -105.91% | -1,774.03% | -1,590.33% |
| 2023 | $5.64M | $-23.88M | 24.80% | -467.93% | -423.39% |
| 2024 | $8.51M | $-16.48M | 39.81% | -255.36% | -193.69% |
| 2025 | $3.85M | $-8.48M | 20.63% | -363.28% | -220.22% |